Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of FHND1002 granules in amyotrophic lateral sclerosis
CTR20253343Phase 2Active
- Sponsor
- Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of FHND1002 in amyotrophic lateral sclerosis (ALS), sponsored by Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.. Started Dec 2025; status: active.
02
Drugs
FHND1002
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on CTR20253343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253343.